Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Metadata listed "Vericel Corp" is incorrect; the filing is for Aastrom Biosciences).
Reporting Period: Quarterly Report (Form 10-Q) for the three months ended September 30, 1998.
Business Stage: Development stage company focused on research and product development for ex vivo production of human cells for cell and gene therapy. The company has not yet generated revenue from product sales and does not expect to be profitable until product sales commence.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1998 | Three Months Ended Sep 30, 1997 |
|---|---|---|
| Total Revenues | $163,000 | $16,000 |
| Total Costs and Expenses | $3,744,000 | $3,856,000 |
| Net Loss | $(3,362,000) | $(3,625,000) |
| Net Loss Per Common Share (Basic & Diluted) | $(0.27) | $(0.27) |
| Cash and Cash Equivalents (Sep 30, 1998) | $6,121,000 | N/A |
| Short-term Investments (Sep 30, 1998) | $6,565,000 | N/A |
| Total Liquid Assets (Cash + Investments) | $12,686,000 | N/A |
| Accumulated Deficit (Inception to Sep 30, 1998) | $(62,479,000) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased significantly to $163,000 from $16,000 in the prior year quarter, driven by new research grants.
- Expense Reduction: Total costs and expenses decreased to $3,744,000 from $3,856,000. Research and development expenses declined to $3,093,000 (from $3,243,000) as product development for the AastromReplicell System approached completion, though grant-related research expenses increased.
- Net Loss Improvement: Net loss narrowed to $3,362,000 from $3,625,000 due to the combination of higher revenues and lower expenses.
- Liquidity Increase: Combined cash, cash equivalents, and short-term investments increased by $1,474,000 from June 30, 1998, to $12,686,000 at September 30, 1998.
Guidance, Outlook, and Risks
- Capital Resources: Management anticipates that current cash resources and interest income will be sufficient to finance operations through mid-1999. Future funding will likely require additional public/private financing or collaborative agreements.
- Workforce Reduction: In November 1998 (post-period), the company implemented a workforce reduction affecting 19 staff positions, expected to reduce operating expenses by approximately 15%.
- Strategic Changes: The company terminated its Distribution Agreement with Cobe BCT Inc. effective November 16, 1998, to consolidate marketing rights for the AastromReplicell System.
- Financing Activity: In July 1998, the company sold $5,000,000 of 1998 Series I Convertible Preferred Stock. An additional $3,000,000 closing is contingent on the common stock trading above $6.00.
- Risks: Significant risks include the inability to obtain regulatory approvals (FDA/CE Mark), failure of clinical trials, dependence on third-party manufacturers for key components, and the uncertainty of securing future capital. The company also notes potential Year 2000 compliance issues with suppliers.
Investor Verification Checklist
- Verify the status of the $3,000,000 contingent closing for the Series II Preferred Stock.
- Confirm the timeline and results of pre-pivotal clinical trials for the AastromReplicell System.
- Assess the impact of the terminated Cobe BCT distribution agreement on the European market launch.
- Monitor the company's cash burn rate against the projected runway to mid-1999.
- Review the progress of Year 2000 compliance assessments for key suppliers and manufacturers.